AstraZeneca PLC
AZNHealthcareNASDAQDrug Manufacturers - General · Last scanned Jun 1, 2026
Scan Results
Daily timeframePart of the healthcare sector, AstraZeneca PLC (AZN) is listed under Drug Manufacturers - General. At a $287.95B market cap, AstraZeneca PLC ranks as a mega-cap company within healthcare. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI.
Market Cap
$287.95B
Beta
0.22
P/E (TTM)
27.92
P/E (Fwd)
23.14
EPS (TTM)
$6.65
EPS (Fwd)
$8.02
ROE
23.5%
ROA
8.5%
Cash
$7.67B
Total Debt
$34.03B
Free CF
$6.56B
52W Change
29.1%
Annual Financials
Cash vs Debt
On the balance sheet, AZN has $7.67B in cash with $34.03B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow comes in at $6.56B, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 23.5% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 8.5% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $44.35B (2022) to $58.74B (2025), reflecting a 32% increase over the period.
The relatively low beta of 0.22 suggests AZN is a less volatile holding compared to the broader index. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing AZN.